Better health is associated with a higher risk of heart disease.

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Better health is associated with a higher risk of heart disease.

Latest News

Dupilumab Most Effective Among Standard Drugs, Biologics in Prurigo Nodularis

Tralokinumab Consistently Effective for Eczema Regardless of Anatomical Site

Predictors Identified for Super-Responder Status to Dupilumab in Atopic Dermatitis

12 Months of Low-Level Laser Therapy at Home Improves Androgenetic Alopecia

BEACON: Positive Results Announced for Briquilimab in Chronic Spontaneous Urticaria

Family Quality of Life Burden in CSU Increased by Lack of Disease Control

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Latest News

News All Time

Psoriasis in 2025: Year in Review

Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life

The HCPFive: Top News for Healthcare Providers from the Week of 12/14

BMI, Inflammatory Bowel Disease Both Show Causal Effect on HS Development

Nemolizumab Rapidly Relieves Itch in Atopic Dermatitis, Prurigo Nodularis

Phase 3 SCALP Study on Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD

Vixarelimab Demonstrates Rapid, Sustained Clinical Benefits in Prurigo Nodularis

Once-Daily Oral Zasocitinib Delivers Strong Phase 3 Efficacy in Plaque Psoriasis

REZOLVE-AA: Phase 2b Data Released on Rezpegaldesleukin for Alopecia Areata

Special Report: Reframing Skin Pain in Atopic Dermatitis Mona Shahriari, MD, FAAD, Andrew Mastro, MS, PA-C

Skin of Color Savvy: Winter Skin Care for Patients of Color, With Heather Woolery-Lloyd, MD, and Aderonke Obayomi, MD, MPH

Addictive Behaviors Linked with Chronic Skin Diseases Such as HS, Psoriasis

Prurigo Nodularis Linked to Increased Risk of Malignancy, Especially Skin Cancers

Dupilumab Shows Greatest Rate of 2-Year Drug Survival Among Atopic Dermatitis Drugs

Imsidolimab’s Biologics License Application for Treatment of GPP Submitted to FDA

Tips on Patient Communication in Dermatology, With Kassandra Holzem, MD Kassandra Holzem, MD

Recommended News For You

recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.

Increased detection of adenomas may reduce colon cancer risk after colonoscopy in FIT-based screening.

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

Could the Prostate Cancer Story of Francis Collins Dissuade Men from Active Surveillance?

Adding cell-based vaccine to liver cancer therapy can slow cancer progression

According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

Recommended Articles For You

Unveiling the Mystery Behind Lymphovascular Invasion

All You Need To Know About Partial Thromboplastin Time (PTT) Test

Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment

The Miracle of Tenecteplase: How This Drug Is Saving Lives

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.